TBIO - Translate Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.76
-0.08 (-1.02%)
As of 3:51PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close7.84
Open7.85
Bid7.80 x 800
Ask7.84 x 1000
Day's Range7.71 - 7.94
52 Week Range5.45 - 14.34
Volume101,987
Avg. Volume267,320
Market Cap465.772M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.77
Earnings DateNov 05, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.67
  • Translate Bio, Inc. (TBIO): Are Hedge Funds Right About This Stock?
    Insider Monkey

    Translate Bio, Inc. (TBIO): Are Hedge Funds Right About This Stock?

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Translate Bio, Inc. (NASDAQ:TBIO). Translate Bio, Inc. (NASDAQ:TBIO) shares haven't […]

  • GlobeNewswire

    Translate Bio Announces Executive Leadership Appointments

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced two executive appointments supporting the Company’s continued growth and leadership in the development of mRNA therapeutics. Frank DeRosa, Ph.D. has been appointed chief technology officer. In addition, Paul Burgess will assume the new role of chief operating officer, overseeing both operations and legal functions for the Company.

  • Seth Klarman Pares Paratek Pharmaceuticals Stake
    GuruFocus.com

    Seth Klarman Pares Paratek Pharmaceuticals Stake

    Renowned guru slims position in struggling biotech that focuses on infectious diseases Continue reading...

  • 5 “Strong Buy” Biotech Stocks With More Than 80% Upside
    InvestorPlace

    5 “Strong Buy” Biotech Stocks With More Than 80% Upside

    For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry. Unlike companies that build up their businesses over time at a steadier pace, biotechs rely on just a few studies or trials of their therapies. As a result, favorable outcomes can catapult share prices upwards. An upset, however, can have the opposite effect.This is why it's essential to do your homework before investing in these often difficult-to-gauge stocks. That's where TipRanks.com comes in. Using the platform, I was able to get access to a host of in-depth market data to help me pinpoint the most compelling investment opportunities in the biotech space.To this end, I found not one, not two, but five biotech stocks poised for huge gains in the long-run. I'm not kidding when I say "huge." I'm referring to more than 80% upside potential from the current share price. Not to mention each has received enough bullish recommendations in the last three months to earn a "strong buy" consensus rating.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy in December Here's the play-by-play. Akebia Therapeutics (AKBA)Source: Shutterstock About 37 million people in the U.S. are affected by chronic kidney disease (CKD). With its commercially available drug, Auryxia, and its other candidate, Vadadustat, in global Phase 3 clinical development, Akebia Therapeutics (NASDAQ:AKBA) wants to provide new treatment options for patients suffering from the disease.While Auryxia sales in its most recent quarter have posed a cause for concern, Piper Jaffray analyst Christopher Raymond is staying onboard. During its third quarter, Auryxia sales came in at $30 million, $2 million less than the five-star analyst estimated. While definitely not the ideal result, the fact of the matter remains that Auryxia has a more important role as a vehicle for Akebia to establish a commercial platform from which to release the "real value driver - Vadadustat."With respect to AKBA's Vadadustat program, both the INNO2VATE and PRO2TECT studies are fully enrolled, meaning that it is on track to report top-line data in Q2 of 2020 and mid-2020, respectively. In two of the drug's Phase 3 pivotal studies conducted by its collaboration partner in Japan, MTPC, data showed that Vadadustat's effect on hemoglobin was sustained in patients with anemia due to CKD, a positive result in terms of efficacy.Bearing this in mind, Raymond maintained his bullish thesis but did reduce the price target from $22 to $15. Despite this drop, this target implies that shares could soar 208% over the next twelve months.Like Raymond, the rest of the Street is betting on this biotech stock. As four "buy" ratings have been assigned in the last three months compared to no "holds" or "sells," the consensus is unanimous: AKBA is a "strong buy." In addition, the $16 average price target indicates 218% upside potential. See the AKBA stock analysis. Aerie Pharmaceuticals (AERI)Source: Shutterstock Aerie Pharmaceuticals (NASDAQ:AERI) is an ophthalmic pharmaceutical company developing innovative treatments for patients with glaucoma and retinal diseases. Despite the major hit shares have taken year-to-date, some analysts argue that AERI is under-appreciated on Wall Street.Part of the problem stems from the company's performance in its most recent quarter. Not only did AERI post an earnings miss, but it also cut its 2019 sales guidance for the second consecutive quarter.However, according to Piper Jaffray's Joseph Catanzaro, there is a positive takeaway from all this. He tells investors that management's outlook for the short-term has become much more "realistic." The analyst adds that he sees little evidence to demonstrate that there has been a reversal in quarterly script trends observed for Rhopressa and Rocklatan, its glaucoma drugs.As a result, Catanzaro kept his "overweight" rating while lowering the price target from $53 to $48. Still, this target conveys his confidence in AERI's ability to climb 159% higher in the next twelve months. * 7 Stocks to Buy With Great Charts All in all, other Wall Street analysts take a similar approach when it comes to AERI. Based on the seven "buys" and no "holds" or "sells" received in the last three months, the bulls have it and the consensus is that the stock is a "strong buy." On top of this, its $42 average price target puts the potential twelve-month gain at 129%. See the AERI stock analysis. Cytokinetics (CYTK)Source: Shutterstock A leader in muscle biology research, Cytokinetics, Inc. (NASDAQ:CYTK) specializes in muscle activators and muscle inhibitors to treat conditions and diseases characterized by muscle weakness, fatigue or diminished muscle function. On the heels of promising new data presented by the company, investor focus has locked in on this biotech.Investors got some good news back in September when CYTK presented data from the Phase 1 study of its CK-274 drug in healthy patients at the annual Heart Failure Society of America (HFSA) meeting. As these results indicated favorable findings in terms of safety and tolerability, CYTK can move forward with its Phase 2 clinical trial to evaluate the drug's effectiveness in patients with obstructive hypertrophic cardiomyopathy (HCM). HCM is an inherited condition that causes part of the heart to get thicker, affecting its ability to pump blood. Given the limited available options in terms of treating heart failure, the drug's implications could fuel massive growth.This outcome prompted a wave of bullish calls to be published, five to be exact. Based on the 100% Street support, the message is clear: CYTK is a "strong buy." Not to mention its $23 average price target suggests there's room for 146% upside from the current share price.One of the analysts singing the biotech's praises is H.C. Wainwright's Joseph Pantginis. Along with his recent "buy" rating, the analyst set a $30 price target, the highest out of the analysts covering the name in the last three months. This means he sees a whopping 216% potential twelve-month gain in store. See the CYTK stock analysis. Novavax (NVAX)Source: Shutterstock Yes, Novavax (NASDAQ:NVAX) is definitely down, but don't count this biotech out just yet. The company, which is best known for producing vaccine candidates, is completely surrounded by bulls. I mean to say that all of the analysts that have covered the stock in the last three months issued a "buy" recommendation, which could be a signal that something positive is around the corner.Oppenheimer analyst Kevin DeGeeter believes that this is in fact the case in spite of the recent headwind it faced. After the company filed an 8-K disclosing that the EMA declined to support use of the conditional marketing authorization pathway for approval of ResVax, its aluminum adjuvanted respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine, in the EU, approval without another clinical trial seems unlikely.However, DeGeeter reminds investors that he is expecting a positive Phase 3 outcome for NanoFlu in the first quarter of 2020. He argues that this could be a potential catalyst for shares. As a result, he remains optimistic about NVAX.In just the past week, H.C. Wainwright's Vernon Bernardino also decided to stay on board. Along with his bullish call, the $17 price target indicates shares could jump a whopping 350% in the next twelve months. * 7 of the Best Internet Stocks to Buy While Bernardino's forecast implies huge upside potential, based on the $23 average price target the Street sees even more. We're talking 512% here. See the NVAX stock analysis. Translate Bio (TBIO)Source: Shutterstock Translate Bio (NASDAQ:TBIO) is pioneering a new approach to treating disease with messenger RNA, with its lead candidate in development for the treatment of cystic fibrosis (CF), a hereditary disease impacting the lungs and digestive system. With the disease affecting 30,000 people in the U.S., there's a huge unmet need.The company has found itself in hot water recently following its decision to terminate its preclinical OTC deficiency program to treat liver disease based on disappointing data."We believe that the success to date in our cystic fibrosis program positions us well to build on our lung delivery platform and maximize the potential of our mRNA technology in additional pulmonary diseases with unmet medical need," CEO Ronald Renaud stated.While this took a toll on shares, Leerink Partners analyst Geoff Porges argues that he views this news as a positive. "It is encouraging to see TBIO commit to this platform and the CF program and is consistent with the groundbreaking potential of its lung LNP delivery system. The decision to abandon the OTCD program was probably relatively easy given the challenges associated with that indication for TBIO and other developers," he noted. To this end, he maintained his bullish call and $20 price target, putting the upside potential at 98%.With 100% Street support, the word on the Street is that TBIO is a "strong buy." Additionally, its $18 average price target suggests a potential twelve-month gain of 81%. See the TBIO stock analysis.TipRanks offers investors the latest insight into eight different sectors by tracking the activity of over 5,000 Wall Street analysts. As of this writing, Maya Sasson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy in December * 7 Unsteady Stocks Investors Should Consider Selling Before 2020 * 7 Entertainment Stocks to Buy to Escape Holiday Blues The post 5 a€œStrong Buya€ Biotech Stocks With More Than 80% Upside appeared first on InvestorPlace.

  • We're Hopeful That Translate Bio (NASDAQ:TBIO) Will Use Its Cash Wisely
    Simply Wall St.

    We're Hopeful That Translate Bio (NASDAQ:TBIO) Will Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Translate Bio to Present at Upcoming Investor Conferences

    LEXINGTON, Mass., Nov. 13, 2019 -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially.

  • Translate Bio, Inc. (TBIO) Reports Q3 Loss, Lags Revenue Estimates
    Zacks

    Translate Bio, Inc. (TBIO) Reports Q3 Loss, Lags Revenue Estimates

    Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of 8.89% and -28.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Translate Bio Announces Third Quarter 2019 Financial Results and Reviews Recent Highlights

    -- Advanced CF program with single-ascending dose (SAD) clinical data presentation and continued enrollment and dosing in multiple-ascending dose (MAD) portion of Phase 1/2.

  • GlobeNewswire

    Translate Bio Presents MRT5005 Data at the 33rd Annual North American Cystic Fibrosis Conference

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today presented data for MRT5005, an inhaled mRNA therapeutic, at the 33rd Annual North American Cystic Fibrosis Conference (NACFC) taking place in Nashville, Tennessee from October 31 to November 2, 2019. MRT5005 is designed to address the underlying cause of cystic fibrosis (CF), regardless of genetic mutation by delivering mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to cells in the lung through nebulization. The poster presentation today and the oral presentation tomorrow describe the previously announced interim results from the single-ascending dose (SAD) portion of a first-in-human Phase 1/2 clinical trial of MRT5005 in 12 patients with CF.

  • Is Translate Bio, Inc. (TBIO) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Translate Bio, Inc. (TBIO) Going To Burn These Hedge Funds ?

    As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the second quarter. We get to see hedge funds' thoughts towards the market and […]

  • GlobeNewswire

    Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced upcoming oral and poster presentations on MRT5005, an inhaled mRNA therapeutic, at the 33rd Annual North American Cystic Fibrosis Conference (NACFC) taking place in Nashville, Tennessee from October 31 to November 2, 2019. The presentations will describe interim results from the single-ascending dose portion of an ongoing, first-in-human Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis (CF). The presentations will include safety and tolerability data from the 12 patients enrolled in the single-ascending dose portion of the clinical trial.

  • GlobeNewswire

    Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the 3rd Annual Chardan Genetic Medicines Conference in New Yok, NY, on Monday, October 7, 2019, at 11:00 a.m. ET. Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The Company’s MRT platform is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. Translate Bio is primarily focused on applying its MRT platform to pulmonary diseases caused by insufficient protein production or where production of proteins can modify disease.

  • GuruFocus.com

    Biggest Hedge Fund Buys of September

    Klarman, Paulson and Singer each reports a significant investment Continue reading...

  • Seth Klarman Further Increases Translate Bio Stake
    GuruFocus.com

    Seth Klarman Further Increases Translate Bio Stake

    Baupost leader ups bet on biotech company that focuses on genetic diseases Continue reading...

  • GlobeNewswire

    Translate Bio Announces Pricing of Public Offering of Common Stock

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its underwritten public offering of 9,000,000 shares of its common stock at a public offering price of $10.00 per share, for aggregate gross proceeds of $90 million, before deducting underwriting discounts and commissions and offering expenses payable by Translate Bio. In addition, Translate Bio has granted the underwriters a 30-day option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

  • GlobeNewswire

    Translate Bio Announces Proposed Public Offering of Common Stock

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has commenced an underwritten public offering of $90 million of its common stock. Translate Bio also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

  • 3 Small-Cap Stock Picks From Seth Klarman
    GuruFocus.com

    3 Small-Cap Stock Picks From Seth Klarman

    The guru has high conviction in these stocks Continue reading...

  • GlobeNewswire

    Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has entered into a multi-year strategic manufacturing agreement with Albany Molecular Research, Inc. (AMRI), a best-in-class, global clinical development manufacturing organization, in support of the planned expansion of Translate Bio’s current Good Manufacturing Practices (cGMP) clinical mRNA manufacturing capabilities. Its preclinical programs are focused primarily on targets in additional pulmonary diseases and also include infectious disease targets for vaccine applications. “At Translate Bio, we recognize the importance of developing scalable manufacturing processes in this innovative field and have made this a priority from the inception of our mRNA therapeutic (MRT) platform,” said Ronald Renaud, chief executive officer, Translate Bio.

  • Baupost's Seth Klarman Dives Further Into Translate Bio
    GuruFocus.com

    Baupost's Seth Klarman Dives Further Into Translate Bio

    Guru adds to position in biotech company that focuses on genetic diseases Continue reading...

  • GlobeNewswire

    Translate Bio Announces Pipeline Program Update

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it is prioritizing the development of pulmonary disease programs including the ongoing development of MRT5005, its clinical candidate for the treatment of CF, as well as the evaluation of targets in additional pulmonary diseases. Additionally, the Company has decided to discontinue the development of MRT5201, a liver-targeted treatment for OTC deficiency.

  • GuruFocus.com

    Frazier Management Llc Buys Translate Bio Inc, Kezar Life Sciences Inc

    Investment company Frazier Management Llc (Current Portfolio) buys Translate Bio Inc, Kezar Life Sciences Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Frazier Management Llc. Continue reading...

  • Do Directors Own Translate Bio, Inc. (NASDAQ:TBIO) Shares?
    Simply Wall St.

    Do Directors Own Translate Bio, Inc. (NASDAQ:TBIO) Shares?

    The big shareholder groups in Translate Bio, Inc. (NASDAQ:TBIO) have power over the company. Large companies usually...

  • Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?
    Motley Fool

    Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?

    Find out how concerned Vertex investors should be about a potential new cystic fibrosis treatment.